


Quick SDW User Guide

Dave Iberson-Hurst, 22nd October 2024

Site

Go to <https://d4k-sdw-staging.fly.dev/>




Click on the big button.

Note: The tooling is a beta, expect one or two issues.

Login

Should see the login screen



Enter the following (this is a guest account)

U: di.h.sdw@proton.me

P: Copenhagen72\$Sunny

Note: There is a small bug where sometimes it does not login. Just try again, usually cures the issue. Think this is a cookie issue.

Home Page

You should see the home page. Five test M11 protocols are loaded.

The screenshot shows the 'dataknowledge' application interface. At the top, there's a navigation bar with 'Import', 'STAGING - MULTIPLE', 'Guest Demo', 'Home', 'Help', and 'Logout'. Below this, a section titled 'Selected Study Operations' contains buttons for 'Delete selected studies' and 'List selected studies'. The main area displays five study cards, each with a title, description, and buttons for 'View Details' and 'View Protocol'. The studies are: Eli Lilly and Company: H2Q-MC-LZZT, University of Pennsylvania: IRB# 821403, Eli Lilly Japan K.K.: ISR-JE-IGBJ, Rheinische Friedrich-Wilhelms-Universität Bonn: DER-202201, and Astellas Pharma: 8062-CL-2002. Each card also includes a 'Phase' label (e.g., Phase III Trial, Phase I Trial) and a '1 version' indicator.

Side By Side View

Select two or more protocols by clicking on the relevant items (anywhere in the boxes), you should see a blue border around the selected items. Click again to de-select, it is just a toggle.

This screenshot is identical to the previous one, but with two study cards selected: 'Eli Lilly and Company: H2Q-MC-LZZT' and 'University of Pennsylvania: IRB# 821403'. These cards are highlighted with a blue border, indicating they are the currently selected items.

Click the “List Selected Studies” button. You should see something like the following.

Please don't click the delete option! ☺

dataknowledge Import STAGING - MULTIPLE Guest Demo Home Help Logout		
Title Page Amendments		
Sponsor Confidentiality Statement		
Full Title:	Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease	RADVAX™: A Stratified Phase I Trial of Pembrolizumab with Hypofractionated Radiotherapy in Patients with Advanced and Metastatic Cancers
Trial Acronym:		
Sponsor Protocol Identifier:	H2Q-MC-LZZT	IRB# 821403
Original Protocol:	No	Yes
Version Number:	(c)	
Version Date:		2017-08-07
Amendment Identifier:	H2Q-MC-LXXT(c)	Unavailable
Amendment Scope:	Global	Unavailable
Compound Code(s):	LY246708	

Click on the Home button (top right) or the logo (top left) to get back to the home page.

Details View

From the home page, clicking the “View Details” button for a study will get you to the details view. Use the view menu at the top to see the other views.

dataknowledge Views Export Transmit STAGING - MULTIPLE Guest Demo Home Help Logout														
RADVAX™: A Stratified Phase I Trial of Pembrolizumab with Hypofractionated Radiotherapy in Patients with Advanced and Metastatic Cancers Sponsor: University of Pennsylvania Phase: Phase I Trial Identifier: IRB# 821403 Version:														
Summary: Study Design														
Overall Design Key aspects of the design	Trial Schema Overall trial schema	Objectives, Endpoints, Estimands Estimands, objectives and associated endpoints												
<p>Key aspects of the trial design are summarised below.</p> <table> <tr> <td>Intervention Model:</td><td>Open Label</td><td>Population Type:</td><td>With disease</td></tr> <tr> <td>Control Type:</td><td>N/A</td><td>Population Diagnosis or Condition:</td><td>Metast: Cancer</td></tr> <tr> <td>Control Description:</td><td>N/A</td><td>Population Age:</td><td>Minimum 18 year of age</td></tr> </table>	Intervention Model:	Open Label	Population Type:	With disease	Control Type:	N/A	Population Diagnosis or Condition:	Metast: Cancer	Control Description:	N/A	Population Age:	Minimum 18 year of age		<p>Objective: To determine the safety of combining Pembrolizumab with hypofractionated radiotherapy in patients with advanced and metastatic cancers.</p> <p>Hypothesis: Pembrolizumab will be safe and well tolerated in patients with advanced and metastatic cancers when combined with hypofractionated radiotherapy.</p>
Intervention Model:	Open Label	Population Type:	With disease											
Control Type:	N/A	Population Diagnosis or Condition:	Metast: Cancer											
Control Description:	N/A	Population Age:	Minimum 18 year of age											
Interventions Overview of Trial Interventions														